Press releases

View Press releases from

20 November, 2019

Further clarification regarding the ROR-gamma project

On November 5, 2019, Karo Pharma Aktiebolag (“Karo Pharma”) issued a press release regarding the Pfizer collaboration and license agreement related to ROR-gamma (“the Pfizer agreement”). The press release informed of Pfizer’s decision to terminate a specific development project, PF-06763809. Karo Pharma has now decided to issue further clarifications on the matter. The supplementary information...

Read more
19 November, 2019

Information Shareholder register

The updated shareholder register is published on our website once per month on our home page usually around one week after month end. However, the shares from the rights issue are not included in the October enclosure and therefore we did not publish these numbers yet. The reason is, that the BTA’s were converted October...

Read more
5 November, 2019

Termination of project regarding ROR-gamma

In December 2011, Karo Pharma Aktiebolag (”Karo Pharma”) entered into a research collaboration and license agreement with Pfizer, with the purpose of discovering and developing substances that hamper the activity in the nuclear hormone receptor ROR-gamma, for treatment of autoimmune diseases. After completion of the initial research collaboration, Pfizer has conducted the development work in-house,...

Read more
31 October, 2019

New number of shares and votes in Karo Pharma

As previously announced, Karo Pharma Aktiebolag (“Karo Pharma”) has completed a rights issue of 60,700,422 shares, with the purpose of repaying a part of the financing of Karo Pharma’s acquisition of Trimb Holding AB as well as to strengthen Karo Pharma’s financial capacity to carry out acquisitions of companies and product portfolios. As a result...

Read more
21 October, 2019

Karo Pharma’s rights issue fully subscribed

Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “IMPORTANT INFORMATION” below.

Read more
8 October, 2019

Karo Pharma postpones publication of the interim report for the period January – September 2019

The board of directors of Karo Pharma Aktiebolag (”Karo Pharma”) has resolved to postpone the publication of the interim report for the period January – September 2019 to 15 November 2019. The previously announced date for publication was 1 November 2019. The delay is due to the ongoing integration process relating to Karo Pharma’s acquisition...

Read more
30 September, 2019

Karo Pharma publishes prospectus relating to the rights issue

 

Read more
30 September, 2019

Karo Pharma publishes prospectus relating to the rights issue

Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “IMPORTANT INFORMATION” below.

Read more
24 September, 2019

Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2 billion

 

Read more
24 September, 2019

Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2 billion

Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “IMPORTANT INFORMATION” below.

Read more
20 September, 2019

EXTRAORDINARY GENERAL MEETING IN KARO PHARMA AKTIEBOLAG ON 20 SEPTEMBER 2019

STOCKHOLM, 20 September 2019 At today’s extraordinary general meeting in Karo Pharma, the following resolution was passed. The general meeting resolved, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors to, on one or several occasions until the Annual General Meeting 2020, resolve on a new issue of shares with...

Read more
19 September, 2019

Karo Pharma’s planned rights issue is intended to amount to approximately SEK 2 billion

As communicated on 12 September 2019, Karo Pharma Aktiebolag (”Karo Pharma”) has completed its acquisition of Trimb Holding AB. The acquisition was mainly financed through a new credit facility and a new bridge loan facility provided by SEB and Swedbank. As previously communicated, Karo Pharma intends to repay the bridge loan facility of MSEK 1,500...

Read more
12 September, 2019

Karo Pharma completes the acquisition of Trimb and carries out management changes

Karo Pharma Aktiebolag (”Karo Pharma”) today announces that the acquisition of all the shares of Trimb Holding AB (“Trimb”) from Avista Capital Partners and other shareholders for MSEK 3,400, which was signed on 21 June, 2019 and approved by relevant competition authorities on 4 September, 2019, has been completed. The acquisition of Trimb is expected...

Read more
4 September, 2019

The Swedish Competition Authority approves Karo Pharma’s acquisition of Trimb and Karo Pharma continues the company’s efforts related to internalisation of sales and marketing

Karo Pharma Aktiebolag (the ”Company” or ”Karo Pharma”) today announces that the acquisition of all the shares of Trimb Holding AB (“Trimb”) from Avista Capital Partners (“Avista”) and other shareholders for MSEK 3,400 (the ”Transaction”), which was signed on 21 June, 2019, has been approved by the Swedish Competition Authority. Previously, clearances have been received...

Read more
28 August, 2019

NOTICE OF EXTRAORDINARY GENERAL MEETING IN KARO PHARMA AKTIEBOLAG

The shareholders of Karo Pharma Aktiebolag, reg. no 556309-3359, are given notice of an Extraordinary General Meeting, to be held on Friday 20 September 2019 at 14:00 CET at Näringslivets Hus, Storgatan 19, Stockholm.

Read more
14 August, 2019

Jon Johnsson appointed new CFO of Karo Pharma

Karo Pharma Aktiebolag (publ) (“Karo Pharma”) has appointed Jon Johnsson as the new CFO of Karo Pharma, replacing Mats-Olof Wallin, who will retire towards the end of the year. Jon will take on his new position on October 1, 2019. Mats-Olof will collaborate with Jon through the middle of December to secure an orderly transition...

Read more
19 July, 2019

Clarification of the statement in the interim report published 19 July 2019 regarding the rights issue with pre-emptive rights

Karo Pharma Aktiebolag (”Karo Pharma”) today published its interim report for the period January – June 2019. On page 2 of the Swedish language version of the interim report, it was, slightly misleadingly, stated that a directed rights issue of approximately MSEK 1,500 with pre-emptive rights for the shareholders of Karo Pharma is planned. Karo...

Read more
21 June, 2019

Karo Pharma acquires Trimb for MSEK 3,400 and intends to carry out a rights issue of approximately MSEK 1,500

Karo Pharma AB (publ) (the ”Company” or ”Karo Pharma”) has today acquired all the shares of Trimb Holding AB (“Trimb”) from Avista Capital Partners (“Avista”) and other shareholders for MSEK 3,400 (the ”Transaction”). The Transaction is expected to contribute positively to Karo Pharma’s market position and create a strong platform for Karo Pharma’s continued growth....

Read more
16 May, 2019

ANNUAL GENERAL MEETING 2019 IN KARO PHARMA AKTIEBOLAG

At today’s annual general meeting of Karo Pharma, the following decisions were passed. The annual general meeting resolved to adopt the income statement and balance sheet for the group and the parent company. The annual general meeting resolved that available funds, including the earnings for the year, were to be carried forward. The annual general...

Read more
16 April, 2019

NOTICE OF ANNUAL GENERAL MEETING IN KARO PHARMA AKTIEBOLAG

The shareholders of Karo Pharma Aktiebolag, reg. no. 556309-3359, are given notice of the annual general meeting to be held at 14:00 CET on 16 May 2019, at Näringslivets Hus, Storgatan 19 in Stockholm.

Read more
9 April, 2019

New date for the annual general meeting of Karo Pharma

STOCKHOLM on 9 April 2019

Read more
3 April, 2019

Christoffer Lorenzen appointed CEO of Karo Pharma; Peter Blom resigning.

The Board of Karo Pharma Aktiebolag (publ) (“Karo Pharma”) has appointed Christoffer Lorenzen as the new CEO of Karo Pharma, replacing Peter Blom. Christoffer will take on his new position on July 1, 2019. Up until this date, and effective as of today, Ulf Mattsson assumes the CEO position on an interim basis. Karo Pharma...

Read more
11 February, 2019

Karo Intressenter’s proposals ahead of the Extraordinary General Meeting in Karo Pharma on 14 February 2019

EQT VIII[1] through Karo Intressenter AB (”Karo Intressenter”) proposes, ahead of the Extraordinary General Meeting in Karo Pharma Aktiebolag (”Karo Pharma”) on 14 February 2019 that the Board Member Håkan Åström is reelected and that Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Christoffer Lorenzen and Åsa Riisberg are elected as new Board Members with Bo Jesper Hansen as Chairman of the Board.

Read more
2 January, 2019

STATEMENT BY THE BOARD OF DIRECTORS OF KARO PHARMA AKTIEBOLAG IN RELATION TO THE INCREASED PUBLIC OFFER FROM EQT VIII, THROUGH KARO INTRESSENTER AB

The Board of Directors of Karo Pharma Aktiebolag has concluded to unanimously recommend that the shareholders of Karo Pharma Aktiebolag accept the increased public offer made by EQT VIII, through Karo Intressenter AB.

Read more